---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201991710085733.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------
部分中文ARAMINE® INJECTION处方资料（仅供参考）

【英文名称】ARAMINE® INJECTION

【适用证】

预防和治疗脊髓麻醉引起的急性低血压状态; 由于出血，对药物的反应，手术并发症以及与肿瘤或创伤引起的脑损伤相关的休克，可以辅助治疗低血压。

它也可用作治疗由心源性休克或败血症引起的低血压的辅助手段。

【用法用量】

Aramine注射仅用于静脉内给药（注射或输注），应仅在一次患者中使用。它不含抗菌​​防腐剂。应该丢弃未使用的解决方案。

因为最大效果不是立即显现，所以在增加剂量之前应该至少经过十分钟。当停用血管加压药时效果逐渐减弱，应仔细观察患者，以便在血压下降过快时立即重新开始治疗。共存休克和酸中毒的患者对血管加压剂的反应可能较差。应采用既定的冲击管理方法，如指示时的血液或液体替换，以及针对特定休克原因的其他措施。

静脉输注（用于辅助治疗低血压）：

推荐剂量为5至100毫克（1.5至10毫升），500毫升氯化钠注射液或5％葡萄糖注射液，调节输注速度以将血压维持在所需水平。已经使用更高浓度的酒石酸间聚胺（150至500mg / 500mL输注液）。如果患者需要额外的盐水或葡萄糖溶液以提供过量血管加压剂的流速，则应相应增加推荐体积（500 mL）的输注液。相反，如果需要较小体积的输注液，则可以将所需剂量的酒石酸间聚胺加入少于500mL的稀释剂中。

兼容性：

除氯化钠注射液和5％葡萄糖注射液外，当向500 mL输液中加入5 mL Aramine注射液时，发现以下输液溶液与酒石酸间苯二酚在物理和化学上相容：Ringer's注射液和乳酸林格氏注射液。当将间苯二酚注射液与输液溶液混合时，应观察无菌预防措施。为减少微生物危害，请在准备后尽快使用。如果需要储存，请在2-8°C下保持不超过24小时。注射液不含抗菌防腐剂，仅供一名患者单独使用。丢弃任何残留物。

直接静脉注射：

在严重休克中，当时间非常重要时，可能需要通过直接静脉内注射给予Aramine注射。建议剂量为0.5至5mg（0.05至0.5mL），然后在500mL稀释剂中输注15至100mg。直接静脉注射未稀释的溶液只应在严重紧急情况下使用，必须采取迅速行动以挽救生命。必须特别小心，以给予适当的剂量。对于直接静脉注射使用较低强度，建议使用0.5 mg / mL的间羟胺注射液。通过用0.9％氯化钠将该10mg / 1mL产物稀释至20mL或使用以其他商品名获得的预稀释溶液，可以获得较低强度的0.5mg / mL间羟胺注射液。

【禁忌】

应避免使用环丙烷或氟烷麻醉，除非临床情况需要此类用途。

对本产品的任何成分（包括亚硫酸盐）过敏。

【INDICATIONS】

Prevention and treatment of the acute hypotensive state occurring with spinal anaesthesia; adjunctive treatment of hypotension due to haemorrhage, reactions to medications, surgical complications, and shock associated with brain damage due to tumour or trauma.

It may also be useful as an adjunct in the treatment of hypotension due to cardiogenic shock or septicaemia.

【DOSAGE】

Aramine injection is for intravenous administration only (injection or infusion) and should be used in one patient on one occasion only. It contains no antimicrobial preservative. Unused solution should be discarded.

Because the maximum effect is not immediately apparent, at least ten minutes should elapse before increasing the dosage. As the effect tapers off when the vasopressor is discontinued, the patient should be carefully observed so that therapy can be reinitiated promptly if the blood pressure falls too rapidly. Patients with coexistent shock and acidosis may show a poor response to vasopressors. Established methods of shock management, such as blood or fluid replacement when indicated, and other measures directed to the specific cause of the shock also should be used.

Intravenous infusion (for adjunctive treatment of hypotension)：

The recommended dose is 15 to 100 mg (1.5 to 10 mL) in 500 mL of sodium chloride injection or glucose injection 5%, adjusting the rate of infusion to maintain the blood pressure at the desired level. Higher concentrations of metaraminol tartrate (150 to 500 mg/500 mL of infusion fluid) have been used. If the patient needs additional saline or glucose solution at a rate of flow that would provide an excessive dose of the vasopressor, the recommended volume (500 mL) of infusion fluid should be increased accordingly. Conversely, if a smaller volume of infusion fluid is desirable, the required dose of metaraminol tartrate may be added to less than 500 mL of diluent.

Compatibility：

In addition to sodium chloride injection and glucose injection 5%, the following infusion solutions were found physically and chemically compatible with metaraminol tartrate when 5 mL of Aramine injection was added to 500 mL of infusion solution: Ringer's injection and lactated Ringer's injection.When metaraminol injection is mixed with an infusion solution, sterile precautions should be observed. To reduce microbiological hazard, use as soon as practicable after preparation. If storage is necessary, hold at 2-8°C for not more than 24 hours. The injection solution contains no antimicrobial preservative and is for single use in one patient only. Discard any residue.

Direct intravenous injection：

In severe shock, when time is of great importance, it may be desirable to administer Aramine injection by direct intravenous injection. The suggested dose is 0.5 to 5 mg (0.05 to 0.5 mL), followed by an infusion of 15 to 100 mg in 500 mL of diluent. Direct intravenous injection of undiluted solution should be employed only in instances of grave emergency when prompt action is imperative to save life. Extreme care must be exercised to give the proper dose. For direct intravenous injection use of a lower strength, 0.5 mg/mL metaraminol injection is recommended. A lower strength 0.5 mg/mL metaraminol injection can be obtained by diluting this 10 mg/1 mL product to 20 mL with 0.9% sodium chloride or by using a pre-diluted solution available under other tradenames.

【CONTRAINDICATIONS】

Use with cyclopropane or halothane anaesthesia should be avoided, unless clinical circumstances demand such use.

Hypersensitivity to any component of this product including sulfites.

---------------------------------------------------------------
详细处方信息以本药内容附件PDF文件（201991710085733.pdf）的“原文Priscribing Information”为准
---------------------------------------------------------------